Weight regain after stopping Ozempic, Wegovy or Mounjaro: what really happens, and why

Almost every patient on a GLP-1 carries the same set of questions, whether they've just started or they're well into treatment. What happens when I stop? Will the weight come straight back? And if it does, was the medication ever actually doing anything?

The honest answer is that most people regain a substantial portion of the weight they lost on a GLP-1, faster than they expect. The finding has held up across every major published study, and it is also the one that gets distorted the most, in both directions. Overstated by people who think GLP-1s are a scam, understated by people selling them. What gets lost in both versions is that the regain data describes a specific scenario, where patients stop abruptly with no plan and no support.

How much do patients regain? How fast?

The first large study to answer the question was the STEP 1 trial extension, published in 2022. STEP 1 had given patients semaglutide (the active ingredient in Ozempic and Wegovy) for 68 weeks alongside lifestyle support, and produced a mean weight loss of around 17%. The extension then followed some of those patients for a year after both the medication and the support were stopped. Within that year, participants regained an average of 11.6 percentage points of the weight they had lost, roughly two-thirds of it. By the end of follow-up at week 120, the semaglutide group still held a net loss of 5.6% from their starting weight, compared with just 0.1% in the placebo group, who had essentially returned to baseline. Some weight loss was preserved, but most of what was lost on the medication came back.

The pattern repeated in SURMOUNT-4, a 2024 trial of tirzepatide (the active ingredient in Mounjaro) published in JAMA. Patients took tirzepatide for 36 weeks and lost an average of 20.9% of their body weight. Half were then continued on the medication and half switched to placebo. The continuation group ended the trial at a 25.3% total loss. The placebo group, having regained 14% of their body weight over the year off treatment, ended at a 9.9% net loss. A post-hoc analysis published in JAMA Internal Medicine in November 2025 found that 82% of the placebo group regained more than 25% of the weight they had lost on Mounjaro. Most of the cardiometabolic improvements they had made on the medication (blood pressure, lipids, fasting insulin) reverted toward baseline alongside the weight.

A 2025 meta-analysis by Berg and colleagues, pooling eight discontinuation studies, reported an average regain of 2.2kg for patients coming off Saxenda (liraglutide) and 9.69kg for patients coming off Ozempic, Wegovy, or Mounjaro. The more weight a patient had lost on the medication, the more they tended to regain after stopping.

The most recent and longest-follow-up data comes from a January 2026 BMJ paper by West and colleagues at Oxford, pooling 11 randomised trials of GLP-1s. They reported an average regain of 0.8kg per month for patients who stopped treatment, with most patients returning to their baseline weight at around 18 months. The Oxford team also found that cardiometabolic markers (blood pressure, blood glucose, cholesterol) returned to pre-treatment levels even sooner, at around 17 months on average.

Most of the regain happens in the first six months. Weight tends to start moving up within two to four weeks of the last dose, climbs through months two to six, and slows after that.

The one published counterweight to this picture is a March 2026 real-world cohort study from Cleveland Clinic, which followed nearly 8,000 patients in Ohio and Florida who had stopped Ozempic, Wegovy or Mounjaro. In that group, patients lost an average of 8.4% of their body weight before discontinuing and regained an average of just 0.5% a year later. The authors are explicit about why the regain looked so much smaller than in the trials. Real-world patients are not doing what trial patients are forced to do. Many had restarted the same medication, switched to a different obesity treatment, or moved onto structured behavioural support. They were not truly off treatment, just managing it differently. The honest reading of the Cleveland data is not that regain is a myth, but that what happens after the medication depends almost entirely on what comes next.

Why does the body do this?

Almost every patient who reads the numbers above lands on the same private fear. If the weight comes back, did the medication actually work? Or am I back to being the problem? This is the fear the diet industry has trained South African patients to feel for thirty years. The honest answer is that regain reflects biology, not a personal failing. Research has been building toward this conclusion for more than a decade. To understand why, it helps to know what was happening in the body during the weight loss itself.

The body defends its fat stores.

The 2025 obesity treatment guidelines from the American Association of Clinical Endocrinology open with a statement that should be read carefully.

Body fat is biologically defended.

The body has a fat-mass range it treats as a baseline, known in obesity medicine as a set point. When fat stores fall below that range, the body responds with a coordinated effort to restore them. This is now the consensus position in the field, built on decades of research into appetite hormones, metabolic rate, and what happens to people in the years after weight loss.

The mechanism is well documented. When a person loses weight through diet alone, levels of leptin (the hormone that signals fullness and energy sufficiency) drop and stay low. Levels of ghrelin (the hormone that drives hunger) rise and stay high. Several other appetite-regulating hormones, including peptide YY and cholecystokinin, shift in the same direction. In 2011, Sumithran and colleagues published a landmark study in the New England Journal of Medicine that measured these hormones in patients who had lost around 13.5kg on a controlled diet. One year later, with most patients having regained some weight, the hormone levels had still not returned to baseline. Hunger ratings were still significantly higher than they had been before the diet, and the body was hormonally still acting as if it had been starved.

The body's response isn't only hormonal. Resting metabolic rate (the calories the body burns at rest) also falls and stays low for years. The most famous demonstration came from a long-term follow-up of Biggest Loser contestants, published in 2016. On the show, contestants had lost an average of 58kg through aggressive caloric restriction and exercise. Six years later, they had regained 41kg of that, about 70% of what they had lost. Their resting metabolic rate was still around 500 calories per day lower than it should have been for their current body composition. In practical terms, this meant their bodies needed about 500 fewer calories per day than someone of the same body composition who hadn't dieted aggressively (roughly the calories in two slices of bread or a small bowl of pasta). The metabolism had reset downward and stayed there.

None of this is a willpower problem. It is a physiological response to weight loss, and it is the same response in every person who loses weight, whether through dieting or medication.

How the medication works.

Ozempic, Wegovy and Mounjaro mimic a hormone the body already makes. GLP-1 is one of several signals the gut releases when food arrives, telling the brain to register fullness and slow down hunger. The medication binds to GLP-1 receptors in the hypothalamus and brainstem, slows the rate at which the stomach empties, and quiets the dopamine pathways that drive food cravings. Patients on a GLP-1 describe this as the quieting of food noise (the background thinking about what to eat next), and as fullness that arrives sooner and lasts longer. For the first time in years, the body's hunger system gives the patient some breathing room.

When the medication is stopped, the artificial signal disappears. The body's own GLP-1 returns to whatever level it naturally produces, which for many people with obesity is lower than average to begin with. The post-weight-loss hormonal environment (high ghrelin, low leptin, suppressed metabolic rate) is still in place. Hunger and food noise return, and the body picks up where it left off, restoring its defended fat mass.

The 2025 AACE guidelines describe the same thing. Regain after a GLP-1 stops is the loss of the medication's effect on appetite and satiety, compounded by the metabolic changes that happened during the weight loss itself. The willpower lie would frame the regain as the patient finally being exposed as weak. The biology tells a different story, where the regain is evidence that the medication had been doing measurable work, and stopping it removed that work. It is not a moral verdict on the patient, but a medical one.

What to do with all of this.

For a patient who has just read all of that, here is the part of the conversation that almost never makes it through. Most discussion of GLP-1 regain stops at the numbers above. When the conversation goes further, the information is usually presented as a reason to give up on the medication entirely, or as confirmation that the patient was always going to fail. Neither is what the research actually shows.

Obesity is a chronic condition, and the medications that treat it work the way medications for other chronic conditions work. Blood pressure does not stay down on its own once medication stops. Cholesterol does not stay improved once a statin is discontinued. The body returns to its baseline biology. This is how chronic conditions work, and it is no longer controversial that obesity is one of them.

There are now two evidence-based approaches that hold the result. One is staying on the medication long-term at a maintenance dose, with the dose stepped down to the lowest level that holds the result. The other is a structured taper at the end of treatment, with substantial behavioural support built underneath it, so that the patient is not simply stopping a medication but transitioning out of one. The trial regain data describes neither of these. It describes the worst-case scenario in which patients stop abruptly with no support and no plan, which is not what good clinical practice looks like and not what real patients in real treatment generally do.

The decision worth making is not whether to start a GLP-1. It is which of these two approaches to start toward, with a clinical team who knows what they are doing. We've written about both in detail in our companion article, Coming off Ozempic, Wegovy or Mounjaro without losing the result: maintenance dosing, tapering, and the work behind both.